UIVI

UIVI is a clinical-stage biotechnology company dedicated to developing innovative therapies for inflammatory eye diseases, with a primary focus on uveitis. The company's lead program is a potent and selective small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), designed to address the underlying inflammatory pathways in non-infectious uveitis. By targeting IRAK4, UIVI aims to provide a more effective and safer alternative to current standard-of-care treatments, such as corticosteroids and systemic immunosuppressants. The company is advancing its lead candidate through clinical trials to demonstrate its potential in reducing ocular inflammation and preventing vision loss.